© 2009 Schattauer GmbH, Stuttgart
New Technologies, Diagnostic Tools and Drugs
Treatment of venous thromboembolism in patients with cancer: Subgroup analysis of the Matisse clinical trials
Frederiek F. van Doormaal1; Gary E. Raskob2; Bruce L. Davidson3; Hervé Decousus4; Alexander Gallus5; Anthie W. A. Lensing6; Franco Piovella7; Martin H. Prins8; Harry R. Büller9
1Academic Medical Center, Amsterdam, The Netherlands; 2University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA; 3University of Washington School of Medicine, Seattle, Washington, USA; 4Hospital de Bellevue, St-Etienne, France; 5Flinders Medical Center,
Adelaide, South Australia, Australia; 6Academic Medical Center, Amsterdam, The Netherlands; 7U.O. Malattie Tromboemboliche, IRCCS
89Policlinico San Matteo, Pavia, Italy; University Hospital of Maastricht, Maastricht, The Netherlands; Academic Medical Center, Amsterdam,
The Netherlands
Summary
In the initial treatment of venous thromboembolism (VTE) fon-daparinux, a pentasaccharide, is a good alternative to heparin. Whether this is also true for cancer patients is unknown. We performed two post-hoc analyses of two randomized studies to compare efficacy, safety and overall survival of fondaparinux to standard initial (low-molecular-weight) heparin (LMWH) treat-ment in cancer patients with venous thromboembolism. Two hundred thirty-seven cancer patients with deep venous throm-bosis (DVT) were initially treated with fondaparinux or enox-aparin. Two hundred forty cancer patients with pulmonary em-bolism (PE) received fondaparinux or unfractionated heparin. The initial treatment was followed by vitamin K antagonists. In DVT patients, the three-month recurrence rate was 5.4% in the Keywords
Venous thromboembolism, cancer, anticoagulants, heparin, pen-tasaccharides
enoxaparin recipients compared to 12.7% in those treated with fondaparinux [absolute difference 7.3%, 95% CI 0.1, 14.5]. A re-currence was observed in 8.9% of the PE patients treated with fondaparinux compared to 17.2% in the unfractionated heparin recipients [absolute difference –8.3, 95% CI –16.7, 0.1]. In both studies no difference in bleeding and overall survival was ob-served. Regarding overall survival and bleeding fondaparinux is comparable to enoxaparin and unfractionated heparin in cancer patients. No significant differences in recurrent VTE were ob-served when comparing fondaparinux with unfractionated or LMWH. Because of study limitations these results should be considered hypothesis-generating.
Thromb Haemost 2009; 101: 762–769
thermore, this analysis indicated a clear survival benefit at three months for the LMWH recipients (RR 0.71 95% CI 0.52, 0.98)
Venous thromboembolism (VTE) often complicates the clinical (5). Long-term treatment in cancer patients was evaluated in course of patients with cancer (1, 2). With standard anticoagulant various studies that compared LMWH with VKA treatment for treatment they have a higher risk of recurrent VTE and an in-3–6 months (6–9). A recent systematic meta-analysis of these creased risk of bleeding compared to non-cancer patients (3, 4). studies showed that long-term LMWH is superior to VKA treat-Standard anticoagulant treatment of VTE starts with heparin ment regarding recurrent VTE (RR 0.51, 95% CI 0.35–0.74) treatment followed by vitamin K antagonists (VKA). A compari-without an increase in bleeding (10). Regarding these beneficial son in recurrence rates of low-molecular-weight heparin effects of LMWH, the question arises how this compares to the (LMWH) versus unfractionated heparin (UFH) in the initial new pentasaccharides, such as fondaparinux. Regarding recur-treatment of VTE in cancer patients showed a moderate statisti-rent VTE rate in cancer patients we have no grounds to expect a cally non-significant advantage of LMWH over UFH (relative difference between the three compounds. With respect to the ef-risk [RR] 0.78, 95% confidence interval [CI] 0.29, 2.08). Fur-fect of fondaparinux on survival in cancer patients, no clinical
Introduction
Correspondence to: F. F. van Doormaal
Department of Vascular Medicine, F4–136 Academic Medical Center
Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands Tel.: +31 20 5665973, Fax: +31 20 5669343 E-mail: F.F.vanDoormaal@amc.uva.nl
Received: September 2, 2008
Accepted after major revision: November 27, 2008
Prepublished online: March 11, 2009
doi:10.1160/TH08-09-0563
analysis.31 Another study for extended treatment of VTE did not report ...New oral anticoagulants in elderly patients with atrial ?brillation. Am J ...
of VTE in cancer patients depends on: - tumour...treatment2 其它治疗因素 EPO(癌性贫血) (癌性贫血...A meta-analysis. 3,322 patients , While ...
of VTE in cancer patients depends on: - tumour...catheter12 chemotherapy9 other treatment2 其它治疗...A meta-analysis. ? ? 3,322 patients , While ...
热门文档